Prostate Cancer

Therapeutic Vaccine Selected for Human Testing

Published in Gene Therapy Weekly, October 19th, 2000

Progenics Pharmaceuticals, Inc. (PGNX), Lake Tahoe, Nevada, and Cytogen Corp. (CYTO) announced a vaccine candidate that the companies will develop for the treatment of prostate cancer.

The vaccine is directed against prostate-specific membrane antigen (PSMA), a unique protein found on the surface of prostate cancer cells, and is designed to stimulate a patient's immune system to recognize and destroy the cancer cells. The preclinical findings were reported at the 7th Annual CaP CURE Scientific Retreat. This in vivo immunotherapy program is being conducted under a joint venture between Progenics and Cytogen.

The vaccine is a genetically-engineered,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2000-10-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry